UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The National Lung Matrix Trial of personalized therapy in lung cancer

Nature (London), 2020-07, Vol.583 (7818), p.807-812

2020

Volltextzugriff (PDF)

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

International journal of molecular sciences, 2023-01, Vol.24 (2), p.1746

2023

Volltextzugriff (PDF)

Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors

Pancreas, 2017-11, Vol.46 (10), p.1354-1358

2017

Volltextzugriff (PDF)

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Frontiers in oncology, 2023-05, Vol.13, p.1163768-1163768

2023

Volltextzugriff (PDF)

Newly qualified doctors' views about whether their medical school had trained them well: questionnaire surveys

BMC medical education, 2007-10, Vol.7 (1), p.38-38, Article 38

2007

Volltextzugriff (PDF)

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours

Endocrine Connections, 2017-11, Vol.6 (8), p.876-885

2017

Volltextzugriff (PDF)

'It gives you an understanding you can't get from any book.' The relationship between medical students' and doctors' personal illness experiences and their performance: a qualitative and quantitative study

BMC medical education, 2007-12, Vol.7 (1), p.50-50, Article 50

2007

Volltextzugriff (PDF)

Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.S48

2021

Volltextzugriff (PDF)

Oncology and medical education-past, present and future

Ecancermedicalscience, 2016, Vol.10, p.ed54-ed54

Cave, Judith

2016

Volltextzugriff (PDF)

122 - Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S53-S53

2023

Volltextzugriff (PDF)

Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S53

2023

Volltextzugriff (PDF)

Towards personalised medicine in lung and thymus neuroendocrine tumours

The lancet oncology, 2017-12, Vol.18 (12), p.1563-1565

2017

Volltextzugriff (PDF)

Explicitly linking teaching and assessment of communication skills

Medical teacher, 2007-05, Vol.29 (4), p.317-322

2007

Volltextzugriff (PDF)

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

Journal of thoracic oncology, 2016-09, Vol.11 (9), p.1511-1521

2016

Volltextzugriff (PDF)

208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107769, Article 107769

2024

Volltextzugriff (PDF)

135 - Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S62-S62

2022

Volltextzugriff (PDF)

Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S62

2022

Volltextzugriff (PDF)

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8600-TPS8600

2023

Volltextzugriff (PDF)

The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis

Journal of clinical pathology, 2016-07, Vol.69 (7), p.612-618

2016

Volltextzugriff (PDF)

THE COMPETENT NOVICE: Dealing with complaints

BMJ. British medical journal (International ed.), 2008-02, Vol.336 (7639), p.326

International edition, 2008

Volltextzugriff (PDF)

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

International immunopharmacology, 2022-09, Vol.110, p.108985-108985, Article 108985

2022

Volltextzugriff (PDF)

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33-S33

2023

Volltextzugriff (PDF)

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33

2023

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBmj Open

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(99)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The National Lung Matrix Trial of personalized therapy in lung cancer

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Newly qualified doctors' views about whether their medical school had trained them well: questionnaire surveys

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours

'It gives you an understanding you can't get from any book.' The relationship between medical students' and doctors' personal illness experiences and their performance: a qualitative and quantitative study

Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?

Oncology and medical education-past, present and future

122 - Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Towards personalised medicine in lung and thymus neuroendocrine tumours

Explicitly linking teaching and assessment of communication skills

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma

135 - Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO

The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis

THE COMPETENT NOVICE: Dealing with complaints

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Aktive Filter

Suchergebnisse filtern